| Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden ZR Chalmers, CF Connelly, D Fabrizio, L Gay, SM Ali, R Ennis, A Schrock, ... Genome medicine 9, 1-14, 2017 | 2901 | 2017 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1247 | 2018 |
| Acquired Resistance to KRASG12C Inhibition in Cancer MM Awad, S Liu, II Rybkin, KC Arbour, J Dilly, VW Zhu, ML Johnson, ... New England Journal of Medicine 384 (25), 2382-2393, 2021 | 556 | 2021 |
| Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer AB Schrock, C Ouyang, J Sandhu, E Sokol, D Jin, JS Ross, VA Miller, ... Annals of Oncology 30 (7), 1096-1103, 2019 | 553 | 2019 |
| Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations AB Schrock, GM Frampton, J Suh, ZR Chalmers, M Rosenzweig, ... Journal of Thoracic Oncology 11 (9), 1493-1502, 2016 | 378 | 2016 |
| Non-V600BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer JC Jones, LA Renfro, HO Al-Shamsi, AB Schrock, A Rankin, BY Zhang, ... Journal of Clinical Oncology 35 (23), 2624, 2017 | 346 | 2017 |
| Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer JJ Lin, VW Zhu, S Yoda, BY Yeap, AB Schrock, I Dagogo-Jack, NA Jessop, ... Journal of Clinical Oncology 36 (12), 1199, 2018 | 297 | 2018 |
| Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence SJ Klempner, D Fabrizio, S Bane, M Reinhart, T Peoples, SM Ali, ... The oncologist 25 (1), e147-e159, 2020 | 277 | 2020 |
| Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers AD Singhi, B George, JR Greenbowe, J Chung, J Suh, A Maitra, ... Gastroenterology 156 (8), 2242-2253. e4, 2019 | 266 | 2019 |
| Structure-based classification predicts drug response in EGFR-mutant NSCLC JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke, YY Elamin, HY Lin, ... Nature 597 (7878), 732-737, 2021 | 232 | 2021 |
| ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ... Journal of the National Cancer Institute 109 (12), djx089, 2017 | 231 | 2017 |
| Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition DA Fabrizio, TJ George Jr, RF Dunne, G Frampton, J Sun, K Gowen, ... Journal of gastrointestinal oncology 9 (4), 610, 2018 | 229 | 2018 |
| Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC JW Riess, DR Gandara, GM Frampton, R Madison, N Peled, JA Bufill, ... Journal of Thoracic Oncology 13 (10), 1560-1568, 2018 | 224 | 2018 |
| Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. DR Spigel, AB Schrock, D Fabrizio, GM Frampton, J Sun, J He, K Gowen, ... Journal of Clinical Oncology 34 (15_suppl), 9017-9017, 2016 | 205 | 2016 |
| Comprehensive genomic profiling of 282 pediatric low‐and high‐grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures A Johnson, E Severson, L Gay, JA Vergilio, J Elvin, J Suh, S Daniel, ... The oncologist 22 (12), 1478-1490, 2017 | 204 | 2017 |
| Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 JS Ross, M Fakih, SM Ali, JA Elvin, AB Schrock, J Suh, JA Vergilio, ... Cancer 124 (7), 1358-1373, 2018 | 184 | 2018 |
| Genomic profiling of small-bowel adenocarcinoma AB Schrock, CE Devoe, R McWilliams, J Sun, T Aparicio, PJ Stephens, ... JAMA oncology 3 (11), 1546-1553, 2017 | 183 | 2017 |
| Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients AP Garner, JM Gozgit, R Anjum, S Vodala, A Schrock, T Zhou, C Serrano, ... Clinical Cancer Research 20 (22), 5745-5755, 2014 | 174 | 2014 |
| Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling AB Schrock, SD Li, GM Frampton, J Suh, E Braun, R Mehra, SC Buck, ... Journal of Thoracic Oncology 12 (6), 932-942, 2017 | 160 | 2017 |
| Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ... Cancer Cell 36 (4), 444-457. e7, 2019 | 157 | 2019 |
